Similarly, a study in 2012 showed that a blood-based Biomarker Panel (CRTAM, CXCR3, FCRL3, KIAA1143, KLF12, TMEM204) could identify men with aggressive prostate cancer, thereby reducing the over-diagnosis and overtreatment that currently results from using PSA alone [12]. Here, KLK3 is linked to prostate carcinoma.